© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90620 refers to a specific vaccine known as the meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C). This vaccine is designed to prevent infections caused by the bacterium Neisseria meningitidis serogroup B in individuals aged 10 years and older. The N. meningitidis serogroup B bacterium is a significant public health concern as it is prevalent worldwide and can be transmitted through respiratory droplets and oral secretions, such as during activities like coughing, kissing, or sharing food and utensils. Infection with this bacterium can lead to severe health complications, including meningitis, which is an inflammation of the protective membranes covering the brain and spinal cord, and sepsis, a life-threatening condition resulting from the body's response to infection. The consequences of such infections can be dire, potentially resulting in fatalities within hours or days, or leading to long-term disabilities such as hearing loss, brain damage, and limb amputation. The vaccine coded as 90620 is administered intramuscularly and follows a two-dose schedule, with the doses given at least one month apart. It is important to note that this code specifically reports the vaccine supply itself, while the administration of the vaccine is reported separately under different codes. This distinction is crucial for accurate medical coding and billing practices.
© Copyright 2025 Coding Ahead. All rights reserved.
The meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), is indicated for the prevention of infections caused by the bacterium Neisseria meningitidis serogroup B in individuals aged 10 years and older. This vaccine is particularly important for those at increased risk of meningococcal disease, which can lead to severe health complications.
The administration of the meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), involves a structured procedure to ensure effective immunization against N. meningitidis serogroup B. The following steps outline the procedure:
Following the administration of the meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), patients are advised on post-procedure care. It is common to experience mild side effects such as soreness at the injection site, low-grade fever, or fatigue. These symptoms typically resolve within a few days. Patients should be informed about the importance of receiving the second dose at least one month after the first to ensure full protection against N. meningitidis serogroup B. Additionally, any unusual or severe reactions should be reported to a healthcare provider immediately for further evaluation and management.
| Short Descr | MENB-4C VACC 2 DOSE IM | Medium Descr | MENB-4C RECOMBNT PROT & OUTER MEMB VESIC VACC IM | Long Descr | Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use | Status Code | Excluded from Physician Fee Schedule by Regulation | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Items and Services Not Billable to the MAC | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | P6D - Minor procedures - other (non-Medicare fee schedule) | MUE | 1 |
| GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | CC | Procedure code change (use 'cc' when the procedure code submitted was changed either for administrative reasons or because an incorrect code was filed) | CR | Catastrophe/disaster related | GA | Waiver of liability statement issued as required by payer policy, individual case | GC | This service has been performed in part by a resident under the direction of a teaching physician | GW | Service not related to the hospice patient's terminal condition | GX | Notice of liability issued, voluntary under payer policy | GZ | Item or service expected to be denied as not reasonable and necessary | JZ | Zero drug amount discarded/not administered to any patient | Q6 | Service furnished under a fee-for-time compensation arrangement by a substitute physician or by a substitute physical therapist furnishing outpatient physical therapy services in a health professional shortage area, a medically underserved area, or a rural area | SK | Member of high risk population (use only with codes for immunization) | SL | State supplied vaccine | X1 | Continuous/broad services: for reporting services by clinicians, who provide the principal care for a patient, with no planned endpoint of the relationship; services in this category represent comprehensive care, dealing with the entire scope of patient problems, either directly or in a care coordination role; reporting clinician service examples include, but are not limited to: primary care, and clinicians providing comprehensive care to patients in addition to specialty care | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2018-01-01 | Changed | First appearance of change in code book. |
| 2017-07-01 | Changed | Revise description to include the complete scientific ACIP acronym. |
| 2017-01-01 | Changed | Code description changed. |
| 2016-01-01 | Added | First appearance in codebook. |
| 2015-02-01 | Added | FDA approval received 2015-01-23. Implementation is 2015-02-01. Payers may decide to implement prior to 2015-02-01. |
| 1991-12-31 | Deleted | Code deleted. |
Get instant expert-level medical coding assistance.